How effective are quadruple therapies as first-line H. pylori eradication therapies?
Borody
Thomas J
TJ
Centre for Digestive Diseases, Sydney, Australia. tborody@zip.com.au
D000328:Adult; D000890:Anti-Infective Agents / Q000627:therapeutic use; D001315:Australia; D001729:Bismuth / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects* / Q000302:isolation & purification; D006723:Hong Kong; D006801:Humans; D008795:Metronidazole / Q000627:therapeutic use*; D009426:Netherlands; D009853:Omeprazole / Q000627:therapeutic use*; D013752:Tetracycline / Q000627:therapeutic use*; D016896:Treatment Outcome
D000890:Anti-Infective Agents; D008795:Metronidazole; D013752:Tetracycline; D009853:Omeprazole; D001729:Bismuth